Abbisko (HKG:2256) said its tumor treatment pimicotinib was accepted for review in the U.S., according to a Hong Kong bourse filing Tuesday.
The drug, which is also known as ABSK021, is meant to treat patients with tenosynovial giant cell tumor.
Pimicotinib is licensed to Germany's Merck KGaA for worldwide commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.